Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00648050 · ClinicalTrials.gov registry record · Phase 1
Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg
A Phase 1 study, sponsored by Mylan Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT00648050 is a Phase 1 study that has completed, run by Mylan Pharmaceuticals. The registered enrollment target is 72 participants.
The verdict
NCT00648050, a Phase 1 study, has completed, sponsored by Mylan Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
The objective for this study was to investigate the bioequivalence of Mylan's verapamil HCl extended-release 300 mg capsules to Schwarz's Verelan® PM extended-release 300 mg capsules following evening administration of a single, oral 300 mg (1 x 300 mg) dose administration under fasting conditions.
Interventions
- DRUG Verapamil Hydrochloride Extended-Release Capsules, 300 mg
- DRUG Verelan® PM Extended-Release Capsules, 300 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2006-03 |
| Est. Completion | 2006-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00648050
The ClinicalTrials.gov registry entry for NCT00648050 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan Pharmaceuticals, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Verapamil Hydrochloride Extended-Release Capsules, 300 mg is the first listed.
NCT00648050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00648050 about?
NCT00648050 is a clinical study titled "Fasting Study of Verapamil HCl Extended-Release Capsules 300 mg to Verelan® PM Extended-Release Capsules 300 mg". The objective for this study was to investigate the bioequivalence of Mylan's verapamil HCl extended-release 300 mg capsules to Schwarz's Verelan® PM extended-release 300 mg capsules following evening administration of a single, oral 300 mg (1 x 300 mg) dose administration under fasting conditions.
What is the current status of trial NCT00648050?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2006-03. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00648050?
The interventions under investigation include: Verapamil Hydrochloride Extended-Release Capsules, 300 mg (DRUG), Verelan® PM Extended-Release Capsules, 300 mg (DRUG).
Who is sponsoring clinical trial NCT00648050?
This trial is sponsored by Mylan Pharmaceuticals, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.